Disclosures. Karri A. Bauer, PharmD, Merck & Co., Inc. (Employee, Shareholder) Levita K. Hidayat, PharmD BCIDP, Merck & Co., Inc. (Employee, Shareholder) Kenneth Klinker, PharmD, Merck & Co., Inc. (Employee, Shareholder) Mary Motył, PhD, Merck & Co., Inc. (Employee, Shareholder) C. Andrew DeRyke, PharmD, Merck & Co., Inc. (Employee, Shareholder)

128. Development of an Analytics Dashboard to Monitor Antimicrobial Selection and Duration for Pneumonia
Ashley Marx, PHAMD3, Sydney E. Brown, BS3, Jason C. Liu, PharmD, MIDS3; Michael J. Swartwood, BSN, RN, CAPM4, Nikolaos Marvogliotos, MD4, UNC Medical Center, Durham, NC; 4UNC Gillings School of Public Health, Durham, North Carolina; 5University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 6University of North Carolina School of Medicine Division of Infectious Diseases, Chapel Hill, North Carolina

Background. Analytical and visual tools can be used to monitor progress for a variety of ASP key performance indicators, but few data describe the process of building disease-state specific tools to retrospectively monitor antimicrobial choice and duration. We describe process and methods for development of a pneumonia dashboard.

Methods. In late 2019, the Carolina ASP began construction of a dashboard to monitor antimicrobial selection and duration in patients admitted with a diagnosis code (ICD-10) consistent with pneumonia. Data extracted from the medical record after discharge included: admission date and time, admission and discharge ICD-10s, inpatient orders and administrations for agents included in the NHSN Antimicrobial Use (AU) option, and antimicrobials ordered at discharge with associated ICD-10. Extracted data fields were validated using a one-month sample. Displays were constructed to trend selection during the first 48 hours of admission, inpatient days of therapy, and total length of therapy (sum of inpatient + outpatient days) for patients who received a discharge prescription for an antimicrobial included in the AU option that was associated with an ICD-10 consistent with pneumonia.

Results. 341 admissions were trended. Within the first two days of admission, monthly proportions of patients receiving an antimicrobial by category were: anti-MRSA therapies (vancomycin, linezolid), 0.20 to 0.75; broad-spectrum beta-lactams (e.g., cefepime, pip/tazo), 0.40 to 0.81; CAP therapies (e.g., ceftriaxone, levofloxacin), 0.48 to 1.00 (Figure). Median inpatient duration of therapy was 5 days (IQR 3-8; range 1 to 68). Total length of therapy was median 6 days (IQR 4-10; range 1 to 68).

Conclusion. Automated reports and visual tools can provide actionable insights for ASP practice. From this dashboard, we identified variable but high rates of antimicrobial selection and duration in patients admitted with diagnoses consistent with pneumonia. Trends observed between Jan 2020 and Mar 2021 are reported.

129. Safety and Cost-effectiveness Analysis Outpatient Continuous Parenteral Antibiotic therapy via a Disposable Elastomeric Pump at Two County Hospitals in Houston, Texas
Ashwaryaa Rao, Bachelor of Science and Arts1; Sam Karimaghaei, BS2; Juliet Chijsjoke, PharmD3; Kristin Constance, MD4; Natalie Finch, PharmD4; BCIDP5; Nino Masazuku, MD5, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas; Harris Health System, Houston, Texas; University of Texas Medical Center at Houston, Houston, Texas; University of Texas in Houston, Houston, TX

Session: P-07. Antimicrobial Stewardship: Program Development and Implementation

Background. Outpatient parenteral antibiotic therapy (OPAT) is a therapeutic option for patients who require longer intravenous (IV) antimicrobial courses, yet do not need to remain hospitalized. Harris-Health system OPAT programs implement a disposable elastomeric continuous infusion pump (eCIP) for IV antibiotics. Here we report the clinic-demographic features, outcomes of a cohort of patients receiving OPAT via eCIP (OPAT-eCIP), as well as the cost-effectiveness of OPAT in comparison to standard inpatient care.

Methods. We retrospectively obtained the clinic-demographic characteristics and outcomes of 91 patients discharged from Harris-Health affiliated hospitals from December 2018 to February 2021 who underwent OPAT-eCIP. We then compared the total costs associated with home OPAT-eCIP care with that of an equivalent of inpatient IV antimicrobial treatment based on previous studies.

Results. We identified 481 total OPAT patients; 91 (18.9%) received intravenous antibiotics via eCIP, with two initiating therapy outpatient. In total, 1925 days of IV antimicrobial therapy were administered outpatient by OPAT-eCIP, with a median treatment course of 12 days. Eighty-three (92.2%) patients completed their antimicrobial course, with 85 (93.4%) cured of respective infections (Table 1). Antimicrobial-associated adverse events and PICC line associated complications were 6.6% and 14.3% respectively. 30-day hospital readmission rates were under 10% with 21 patients (23.1%, 28 total visits) presenting to the emergency room over the course of IV therapy. Estimated costs of OPAT-eCIP care over the study period ranged from $417,000-$576,750 with costs of equivalent inpatient care estimated at $2,945,250 to $3,927,000; estimated overall cost savings of OPAT-eCIP were $2,368,500 to $3,509,900 (Table 2).

Table 1. Characteristics and Outcomes of Patients Receiving Continuous IV Antibiotics via Disposable Elastomeric Pump

| Variables | Median (IQR) |
|-----------|--------------|
| Age (years) | 67 (49-78) |
| Males (%) | 64 (47-74) |
| Category of Infection, n (%) | | |
| Community-acquired | 74 (58-83) |
| Healthcare-related | 26 (17-42) |
| Category of Infection, n (%) | | |
| Category of Infection, n (%) | | |
| Initial Inpatient Duration of Therapy, d | 7 (5-10) |
| Total Length of Therapy, d | 14 (9-19) |
| Outcomes | | |
| Completion of Antibiotic Course, n (%) | 83 (65-100) |
| Cure Rate, n (%) | 3 (12-50) |
| Patient Discharge, n (%) | 85 (65-100) |
| Hospital Readmission within 30 days, n (%) | 8 (6-12) |
| PICC Line Complications, n (%) | 0 (0-0) |

Table 2. Cost Analysis Comparison of OPAT-eCIP therapy versus inpatient antimicrobial therapy in patients from December 2018 to February 2021

| Cost Category | OpAT-eCIP | Inpatient Antimicrobial Therapy |
|---------------|-----------|---------------------------------|
| Cost Per Inpatient Day ($) | 1,000 | 2,000 |
| Cost Per Antibiotic Dose ($) | 30-40 | 30-40 |
| Cost Per ED Visit ($) | 500,000 | 200,000 |
| Cost Per Home Health Visit ($) | 500 | 500 |
| Estimated total costs ($) | 1,000,000 | 2,000,000 |
| Estimated cost savings ($) | 1,000,000 | 1,000,000 |

*Costs calculated using three days of continuous antibiotic infusion therapy (30 days OPAT-eCIP = Equivalent to 40 inpatient days of durable PICC line and extended parenteral pumps (EPP) (Emergency Department)
Conclusion. OPAT-eCIP therapy in a cohort of patients was highly effective and well-tolerated. While ED visit frequency indicates the necessity of close patient monitoring, low 30-day hospital readmission rates were encouraging. Along with the above, the significant cost savings demonstrated when compared with standard inpatient antimicrobial therapy suggest that OPAT-eCIP should be increasingly utilized as an effective therapeutic option.

Disclosures. All Authors: No reported disclosures

130. Effects of COVID-19 on a Complex Behavioral Intervention to Improve the Diagnosis and Management of UTI in Nursing Homes

James H. Ford, II, PhD; Sally Jolles, MA; Dee Heller, LPN; Katie Selle, MA, RN-BC; Daniela Uribe-Cano, MPH; Susan Nordman-Oliveira, MSSE; Jessica Irvine, BS; DaRae Coughlin, NP; Christopher J. Grimm, MD, PhD; 1University of Wisconsin-Madison, Madison, WI; University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; 2Edgewood College, Madison, Wisconsin; 3University of Wisconsin – Madison, Madison, Wisconsin

Session: P-07. Antimicrobial Stewardship: Program Development and Implementation

Background. Half of all urinary tract infections (UTI) are probably unnecessary. We conducted a cluster-randomized trial in which a toolkit to enhance the diagnosis and treatment of UTIs was introduced in study NHs via usual implementation versus an enhanced implementation approach based on external facilitation and peer comparison reporting.

Methods. Thirty Wisconsin NHs were randomized to each treatment arm in a 1:1:1 ratio. NHs used an online portal to report urine culture and antibiotic treatment data over a 6-month pre-intervention period (Jan-June 2019), a pre-COVID 8-month post intervention period (July 2019-Feb 2020) and an 8-month post-COVID intervention period (Mar-Oct 2020). Study outcomes included urine culture (UC), antibiotic start (AS), and antibiotic days of therapy (DOT) rates per 1,000 resident days. A generalized estimating equation model for panel data was used to assess differences in study outcomes between treatment arms before and after onset of the COVID-19 pandemic. STATA 16.1 was used for all analyses.

Results. A total of 802 UCs (457 pre-COVID, 345 post-COVID), 724 AS (401 pre-COVID, 323 post-COVID), and 6,454 DOT (3553 pre-COVID and 2901 post-COVID) were reported over the 16-month intervention period. No significant differences in the study outcomes were observed during the pre-COVID intervention period, however, UC rates in NHs assigned to the usual care arm of the study increased while those in the enhanced arm declined following onset of COVID-19 (Figure 1). AS and DOT rates followed a similar pattern although the differences between the study arms were not statistically significant.

Figure 1. Post Implementation Periods

| Period 1 (Before COVID-19) | Period 1 (after COVID-19) |
|---------------------------|---------------------------|
| Control (Mean) | Intervention (Mean) | P-value | Control (Mean) | Intervention (Mean) | P-value |
| Uric Culture (per 1,000 resident days) | 1.17 | 1.03 | 0.33 | 1.25 | 0.88 | 0.02 |
| Antibiotic Starts (per 1,000 residents) | 0.97 | 0.93 | 0.75 | 1.22 | 0.86 | 0.08 |
| Days of Therapy (per 1,000,000) | 8.02 | 7.84 | 0.25 | 9.57 | 7.54 | 0.16 |

Conclusion. Our findings suggest that NHs assigned to usual implementation regressed in their diagnosis and treatment of UTIs during the COVID-19 pandemic while those receiving external facilitation and peer comparison reports were more resilient to the effects of COVID-19.

Disclosures. All Authors: No reported disclosures

131. A Pharmacist Led Antimicrobial Stewardship Pilot at Discharge Improves Outpatient Antibiotic Utilization

Kayla Hriyak, PharmD; Geena Kludjian, PharmD; Jason C. Gallagher, PharmD, FIDP, FCCP, FIDSA, BCPS; Jason C. Gallagher, PharmD, FIDP, FCCP, FIDSA, BCPS; Marissa Cavaressa, PharmD; Temple University School of Pharmacy, Philadelphia, Pennsylvania; 2Temple University, Philadelphia, PA

Session: P-07. Antimicrobial Stewardship: Program Development and Implementation

Background. The impact of antimicrobial stewardship programs has been well observed in institutional settings; however, patients complete over one-third of their antibiotic course after discharge. This creates a gap in stewardship efforts at transitions of care. We studied whether pharmacist review of antibiotic prescriptions at discharge would improve outpatient antibiotic prescribing.

Methods. This was a pilot project of patients in medicine wards of an academic medical center who were discharged on oral antibiotics between February and May 2021. Patients who were pregnant, <18 YO, had COVID-19, or leaving against medical advice were excluded from evaluation. For the pilot, a verification queue was created in the electronic health record (EHR) system where orders for discharge antibiotics were reviewed by investigator pharmacists before prescriptions were electronically sent to outpatient pharmacies. During the pilot, prescriptions were reviewed Monday-Friday afternoons from 12pm-6pm. Data was collected on incidence, type, and acceptance rate of pharmacist interventions, and a cost savings analysis was conducted with values calculated by the EHR system.

Results. There were 149 patients included with oral antibiotic prescriptions reviewed during the time frame. Of those patients, 48 (32.2%) had at least one prescription that was intervened on by a pharmacist. A total of 55 interventions were made with an acceptance rate of 76%. The median time for pharmacist review was 10 minutes (IQR 5.15). Patients who received infectious diseases (ID) consultation during admission required less intervention than patients without expert consultation but did not reach significance (8/35 and 47/114 respectively, p=0.07). The total cost savings associated with all interventions was $20,743.00.

Table 1. Interventions

| Intervention Type | N (%) |
|-------------------|-------|
| Incorrect dosing  |       |
| - Underskipped     | 16 (29.1) |
| - Overskipped      | 8      |
| - No directions    | 1      |
| Antibiotic selection | 9 (15.4) |
| - Organism resistant to prescribed antibiotic | 5 |
| - S. aureus        | 2      |
| - S. pneumonia     | 1      |
| - Duplicate coverage | 2      |
| - Additional drug required | 1 |
| - Antibiotic streaming | 1    |
| Lab required       | 4 (7.3) |
| No indication for antibiotics | 4 (7.3) |
| Drug-drug interaction | 3 (5.4) |

Conclusion. Direct pharmacist review and intervention at discharge improved the prescribing of oral antibiotics within our institution during this pilot. Considering that this was conducted part-time in a subset of hospitalized patients during a limited time period, significant cost savings are possible with greater implementation.

Disclosures. Jason C. Gallagher, PharmD, FIDP, FCCP, FIDSA, BCPS, Astellas (Consultant, Speaker’s Bureau); Merck (Consultant, Grant/Research Support, Speaker’s Bureau); Qpex (Consultant); scramble Pharmaceuticals (Consultant); Shionogi (Consultant) Jason C. Gallagher, PharmD, FIDP, FCCP, FIDSA, BCPS, Astellas (Individual(s) Involved: Self); Speakers’ bureau; Merck (Individual(s) Involved: Self); Consultant; Grant/Research Support; Navirea; Consultant; Qpex (Individual(s) Involved: Self); Consultant; Shionogi (Individual(s) Involved: Self); Consultant; Marissa Cavaressa, PharmD, Merck (Grant/Research Support)

132. Standardized Antimicrobial Administration Ratios to Guide Antimicrobial Stewardship in the Neonatal Intensive Care Unit: A Single Center Experience

Steven Smoke, PharmD; Uzma Hasan, MD; Eileen Steffen, RNC-NIC; 1Kamtron Vangvanichyakorn, MD; 2Saint Barnabas Medical Center, Milltown, New Jersey; Disclosures: Steven Smoke, PharmD, Karais (Advisor or Review Panel member); Shionogi (Scientific Research Study Investigator, Advisor or Review Panel member)

Session: P-08. Antimicrobial Stewardship: Special Populations

Background. Antimicrobial stewardship (AMS) is particularly challenging in the neonatal population. Both under- and overuse can negatively impact outcomes. There are limited reports of strategies to improve AMS in the neonatal population. Standardized Antimicrobial Administration Ratios (SAARs) are novel metrics of antimicrobial use, recently introduced for neonatal populations by the National Healthcare Safety Network (NHSN). We describe our experience using SAARs to guide AMS in the neonatal intensive care unit (NICU).

Methods. This was a retrospective study conducted from January 2020 to April 2021. A team consisting of AMS and NICU department staff identified and implemented AMS strategies. Based on a review of NICU SAAR data, a goal was set to reduce third generation cephalosporin use by encouraging amoxicillin-clavulanate use when appropriate. The pre-implementation period was January 2020 to May 2020 and the post-implementation period was July 2020 to April 2021. Antibiotic use was measured as SAARs and compared between study periods. The primary outcome was the neonatal SAAR for third generation cephalosporins. Secondary outcomes included SAARs...